Abstract:

Classical chemotherapeutic drugs have an effect in the cell cycle with the arrest, the stop of cell replication and the induction of apopitosis. However, because these medications are not specific to the cancer cell, use over certain doses can cause fatal toxicities. Thus, although the effectiveness of the drug depends on the dose, the dose is limited to a certain level due to toxicity. Limited activity due to high side effects has led to the development of new molecules in the treatment. These newly developed drugs are created by the combination of immunoconjugates with an antigen developed against a cancer cell and a cell-toxic agent (citotoxic drugs, radioizotopes, toxins) with a strong bond. This bond ensures that the antibodies and agents do not disappear without reaching the cell and that the agents reach the cell. This mechanism makes the immunoconjugates specific to the cancer cell. In this article, we aimed to summarize the characteristics of immunoconjugates that may be the popular treatment of the future and why they are more effective.

Keywords: